MARKET

ENVB

ENVB

Enveric Biosciences Inc
NASDAQ
1.030
+0.010
+0.99%
Opening 11:31 03/28 EDT
OPEN
1.020
PREV CLOSE
1.020
HIGH
1.040
LOW
1.000
VOLUME
177.75K
TURNOVER
0
52 WEEK HIGH
6.98
52 WEEK LOW
0.6490
MARKET CAP
5.56M
P/E (TTM)
-0.1274
1D
5D
1M
3M
1Y
5Y
Enveric Biosciences Inc <ENVB.OQ> expected to post a loss of $1.28 a share - Earnings Preview
Enveric Biosciences Inc expected to post a loss of $1.28 a share - Earnings Preview. The company is expected to report results on May 13 for the period ending March 31 2024. The mean analyst estimate for Enveric is for the company to lose $ 1.28 per share.
Reuters · 19h ago
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Enveric Biosciences shares financial results for the fourth quarter of 2023 and the fiscal year ended December 31, 2023. Nasdaq-listed psychedelics biotech Enveric is advancing two drug candidates for depression and anxiety disorders. The company has discovered over 1,000 psychedelic-inspired compounds in the past year.
Benzinga · 1d ago
Enveric Biosciences reports Q4 results
Seeking Alpha · 2d ago
Enveric Biosciences Inc: Current report
Press release · 2d ago
*Enveric Biosciences 4Q Loss $3.44M >ENVB
Dow Jones · 2d ago
Press Release: Enveric Biosciences Reports -2-
Are efficacious or safe in preclinical or clinical trials. Enveric faces a number of risks and uncertainties. These include the ability to continue as a going concern and manage its future growth effectively. The company disclaims any intention or obligation to revise any forward-looking statements.
Dow Jones · 2d ago
Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
Enveric Biosciences reports financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023. Selected neuroplastogen lead candidate EB-003 as a potential first-in-class therapeutic option for depression and anxiety disorders. Company continues to progress IND-enabling preclinical work for EB-002.
Dow Jones · 2d ago
Weekly Report: what happened at ENVB last week (0318-0322)?
Weekly Report · 3d ago
More
About ENVB
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.

Webull offers Enveric Biosciences Inc stock information, including NASDAQ: ENVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENVB stock methods without spending real money on the virtual paper trading platform.